Washington, Jun 30 (EFE).- German biopharmaceutical company CureVac said Wednesday its Covid-19 vaccine showed an efficacy of 48 percent in final trial results.
CureVac doses are based on messenger RNA (mRNA), also used in vaccines by Moderna and Pfizer-BioNTech, which both showed much higher efficacy of around 95 percent against the original strain. Recent studies show both also offer strong protection against newer virus variants.
“In the unprecedented context of 15 strains circulating within the study population at the time of final analysis, CVnCoV demonstrated an overall vaccine efficacy of 48% (vaccine 83 vs. 145 placebo) against Covid-19 disease of any severity,” the firm said in a statement.
In June, the company had revealed in its second preliminary analysis that the effectiveness of its vaccine reached only 47 percent in preventing the coronavirus.
CureVac on Wednesday noted that its vaccine showed “significant protection” among participants in the 18-60 age group, reaching overall 53 percent “against disease of any severity and across all 15 identified strains.”
That percentage, it added, rose to 77 percent for “moderate to severe” disease and provided “100% protection” to participants within that age range “against hospitalization or death.”
The laboratory, which collaborates with the German chemical and pharmaceutical group Bayer for the development and distribution of the vaccine, noted that the data has been communicated to the European Medicines Agency (EMA).
Some 40,000 people from 10 countries in Latin America and Europe participated in the study, of which 9 percent were over 60 years old.
Among the 228 Covid cases recorded during the trial, 83 were vaccinated and 145 were placebo participants, according to the data from the final analysis. EFE